HCPCS Code J7330: Autologous Cultured Chondrocytes Billing Guide

Key Takeaways

HCPCS Code J7330 describes autologous cultured chondrocytes, implant (MACI) – used to bill for the tissue product itself, not the surgical procedure.

J7330 is classified as a Part B MAC drug under carrier judgment coverage – Medicare reimbursement is not guaranteed and varies by MAC jurisdiction.

A companion CPT code for the surgical implantation procedure must always accompany J7330 on the claim – submitting J7330 alone is a leading denial trigger.

Pabau’s claims management software helps orthopedic and regenerative medicine practices track J7330 claims, modifier usage, and prior authorization status in one workflow.

Orthopedic practices billing MACI implant procedures face a billing structure that differs from most surgical drug codes. The implant product and the surgical procedure require separate codes, separate documentation logic, and in many cases separate prior authorization processes. Missing any one of these steps sends the claim to denial. HCPCS Code J7330 covers autologous cultured chondrocytes, implant (MACI) – a biologic tissue product manufactured from a patient’s own cartilage cells and implanted during a second-stage surgical procedure to repair articular cartilage defects, typically in the knee.

This guide covers how to bill HCPCS Code J7330 correctly, what documentation Medicare and commercial payers require, which companion CPT codes apply, and how the buy-and-bill reimbursement model works for this product.

HCPCS Code J7330: Definition and Clinical Description

HCPCS Code J7330 has a long description of “Autologous cultured chondrocytes, implant” and a short description of “Cultured chondrocytes implnt.” The code falls under HCPCS Level II, in the category of Drugs Administered Other than Oral Method (J-codes). CMS assigned it Part B MAC jurisdiction, meaning your regional Medicare Administrative Contractor processes claims for this code rather than a DME MAC.

The code was added to HCPCS on January 1, 2001, predating the commercial approval of the branded MACI product. Coverage under Medicare is listed as “Carrier judgment,” meaning individual MACs determine coverage based on their own Local Coverage Determinations (LCDs) rather than a uniform National Coverage Determination (NCD). Always check your MAC’s active LCD before submitting a J7330 claim.

According to the Centers for Medicare and Medicaid Services (CMS), HCPCS Level II codes are maintained annually and are the required coding system for drugs, biologics, and supplies not described by CPT. J7330 specifically captures the tissue implant product, not the surgical act of implanting it.

What Is MACI (Matrix-Induced Autologous Chondrocyte Implantation)?

MACI is the brand name for the autologous cultured chondrocyte product manufactured by Vericel Corporation. The treatment follows a two-stage process. First, a surgeon performs an arthroscopic biopsy to harvest cartilage cells (chondrocytes) from a non-load-bearing area of the patient’s knee. Those cells are sent to a laboratory where they are cultured and seeded onto a porcine collagen membrane. The resulting implant is then shipped back to the facility for a second-stage open surgical procedure, during which the surgeon trims the membrane to the defect size, applies fibrin glue, and secures the implant over the cartilage lesion.

FDA-approved indications include symptomatic, full-thickness cartilage defects of the knee (chondral or osteochondral) in skeletally mature patients. MACI is not indicated for osteoarthritis. This distinction matters for medical necessity documentation – payers routinely deny claims where the diagnostic codes suggest degenerative joint disease rather than a discrete chondral defect.

Companion CPT Codes for MACI Implantation

J7330 bills only the tissue product. The surgical implantation procedure requires a separate CPT code on the same claim. Failing to include the procedure code – or submitting J7330 without a corresponding operative note – is one of the most common reasons for denial on these claims.

The dedicated Category I CPT code for the Stage 2 MACI implantation procedure is CPT 27412 – Autologous chondrocyte implantation, knee. Stage 1 is reported with CPT 29870 for the diagnostic arthroscopy and cartilage biopsy. Sports medicine practices and orthopedic surgeons billing MACI should confirm current CPT validity and any payer-specific requirements with their MAC before submitting, but 27412 is the standard code for autologous chondrocyte implantation in the knee and should be used in place of unlisted codes whenever it accurately describes the service.

CPT 27412 is the standard code for the Stage 2 MACI implantation in the knee and should be reported alongside J7330 for the implant product itself. Unlisted procedure codes such as 27599 (unlisted procedure, femur or knee joint) should be reserved for unusual presentations where 27412 genuinely does not describe the service performed – for example, an autologous chondrocyte implantation outside the knee. When an unlisted code is necessary, attach the operative report, a letter of medical necessity, and a crosswalk to the closest named procedure code explaining why 27412 (or another listed code) does not adequately describe the service. Complex biological procedure billing requires this same documentation discipline across multiple specialty areas.

Medicare Coverage and Reimbursement for HCPCS Code J7330

Medicare coverage for J7330 is classified as “Carrier judgment,” which means no uniform national coverage determination exists. Each Part B MAC evaluates MACI claims under its own LCD or case-by-case clinical review. This creates meaningful variation in coverage outcomes depending on the MAC jurisdiction where your practice is located.

Under Medicare Part B, physician-administered drugs and biologics billed with J-codes are typically reimbursed at 106% of the Average Sales Price (ASP) – the product’s ASP plus a 6% add-on – when administered in a physician office or outpatient setting. The CMS Physician Fee Schedule lookup tool provides current payment rates, though ASP for J7330 updates quarterly and should be verified against the current quarter’s CMS ASP payment limit file before submitting claims. Because specific dollar amounts change quarterly, this guide does not publish fixed reimbursement figures.

The buy-and-bill model applies to MACI. Your practice or facility purchases the implant directly from Vericel Corporation, uses it during the procedure, and then bills J7330 to the payer for reimbursement. The difference between your acquisition cost and the payer’s reimbursement rate is a significant financial variable. Practices using claims management workflows that track product cost against reimbursement by claim can identify shortfalls before they become systemic losses.

Place of Service Considerations

MACI implantation is a surgical procedure requiring a hospital outpatient department (HOPD), ambulatory surgery center (ASC), or inpatient setting. Physician office billing for the implantation procedure itself is not appropriate. The place of service code on the claim affects both the fee schedule applicable to the surgical CPT and the facility’s separate claim for the technical component.

When the procedure occurs in an HOPD or ASC, the facility bills for the implant product through its own claim (typically a UB-04). The physician bills the professional component (the surgical CPT) on a CMS-1500. J7330 is most often billed on the facility claim in this context. Confirm with your billing team and the facility which entity is billing the implant product to avoid duplicate claims.

Simplify Complex Billing Workflows

Pabau helps orthopedic and regenerative medicine practices manage J-code claims, prior authorization tracking, and documentation workflows in one platform. See how it works for your practice.

Book a demo

Prior Authorization Requirements for J7330

Prior authorization is required by most commercial payers for MACI and is increasingly common for Medicare Advantage plans. The prior authorization process for J7330 typically evaluates both medical necessity for the implant product and the surgical procedure together – submitting them as separate requests to different departments within the same payer is a common workflow error that delays approval.

Most payers require the following before approving a MACI prior authorization request:

• MRI confirming a focal articular cartilage defect (chondral or osteochondral) with defect size and location documented
• Documentation that conservative treatment (physical therapy, injections, or prior arthroscopic procedures) was attempted and failed, with specific timeframes
• Confirmation that the patient has a symptomatic lesion in a skeletally mature knee without evidence of diffuse osteoarthritis
• Surgeon’s letter of medical necessity specifically citing the FDA-approved indications for MACI
• Stage 1 arthroscopy report confirming the defect characteristics that meet criteria

For regenerative medicine practices offering cartilage repair procedures, the prior authorization record should be linked to the patient’s chart so that the approval number, approved service dates, and approved quantity are available at the time of claim submission. A prior authorization that expires before the stage 2 procedure is performed – which can happen when surgical scheduling is delayed – will result in denial even if the clinical criteria remain met.

Documentation Requirements to Support J7330 Claims

Medicare’s carrier judgment coverage designation for J7330 places a higher documentation burden on practices than codes with established NCDs. The operative note alone is insufficient. Claims reviewers – both on initial submission and on audit – look for a complete clinical record connecting the diagnosis, the surgical findings, and the medical necessity of MACI specifically.

Required documentation elements for J7330 claims typically include:

• Diagnostic imaging reports (MRI) with the radiologist’s read confirming focal cartilage defect, lesion size (in cm²), and grade
• Stage 1 arthroscopy operative note documenting defect location, defect measurements, and confirmation that autologous chondrocyte harvest was performed
• Laboratory confirmation that the harvested cells were sent to a qualified laboratory for culturing (manufacturer processing documentation from Vericel)
• Stage 2 operative note documenting defect preparation, membrane sizing, fibrin glue application, and implant placement
• Product label from the MACI implant lot used, documenting the quantity of implant applied (used for J7330 unit billing)
• Discharge summary or post-operative notes confirming the procedure was completed without complication, if applicable

Maintaining structured digital forms for each stage of the MACI process – from the initial consultation through post-operative documentation – reduces the risk of audit exposure by ensuring all required elements are captured systematically rather than relying on free-text operative notes alone. Practices with compliance requirements in musculoskeletal care already understand this documentation discipline well.

Diagnosis Codes to Use with J7330

The ICD-10-CM diagnosis code submitted with J7330 must reflect a focal articular cartilage defect, not osteoarthritis. Using an osteoarthritis code (M17 series) as the primary diagnosis when billing MACI is a near-certain path to denial – MACI is not FDA-indicated for osteoarthritis, and payers review this actively.

Code selection should reflect the specific clinical scenario documented in the operative report. Specificity matters: right vs. left, initial vs. subsequent encounter for traumatic codes, and the precise cartilage structure affected. A general chondromalacia code without supporting documentation of lesion severity will invite additional documentation requests from payers.

Common Denial Reasons and How to Appeal J7330 Claims

J7330 claims fail for predictable reasons. Understanding the denial pattern before it becomes a trend is the difference between a manageable revenue cycle and a chronic reimbursement problem on a high-cost biologic product.

The most frequent denial reasons for J7330 include:

• No prior authorization on file: The most common commercial payer denial. The fix is a retrospective authorization request (where the payer allows it) accompanied by the full clinical record and a peer-to-peer review request if the initial request is denied.
• Missing companion CPT code: J7330 submitted without the surgical procedure code creates a claim that looks like a drug was billed without an associated service. Ensure the operative CPT and J7330 share the same date of service.
• Diagnosis code mismatch: Osteoarthritis codes as primary diagnosis. Correct by resubmitting with the appropriate focal defect code supported by imaging and operative documentation.
• Carrier judgment denial (Medicare): The MAC reviewed the clinical record and did not find the procedure medically necessary under its LCD. Appeal through the Medicare redetermination process with additional clinical evidence, peer-reviewed literature supporting MACI for the specific defect characteristics, and a physician attestation letter.
• Unit billing error: J7330 is billed per implant. If more than one sheet of MACI was used, the unit count on the claim must reflect this. Billing one unit when two were used results in underpayment; billing two units with only one used documented creates an overpayment situation subject to audit.

For practices managing a volume of MACI cases, compliance management tools that flag claims missing required companion codes or prior authorization references before submission reduce the denial rate at the front end rather than through retrospective appeals.

Appealing a carrier judgment denial for Medicare requires submitting through the Redetermination level (Level 1) within 120 days of the claim denial date. Include the full operative record, diagnostic imaging reports, a literature summary supporting MACI’s clinical evidence base, and documentation of why alternative treatments were insufficient for this patient. HIPAA-compliant record management is essential for assembling this documentation efficiently during appeal deadlines.

Expert Picks

Need a broader overview of orthopedic and sports medicine billing workflows? Pabau’s sports medicine software page outlines how the platform supports complex procedure tracking and documentation for musculoskeletal specialties.

Managing drug administration claims across multiple J-codes? Pabau’s claims management software centralizes J-code billing, modifier tracking, and payer-specific rules in one workflow.

Want to standardize pre-authorization and clinical documentation workflows? Pabau’s digital forms allow practices to build structured intake and clinical documentation templates that capture the data points payers require at audit.

Looking for HCPCS code references across your drug administration claims? AAPC Codify’s HCPCS lookup provides code properties, coverage rules, and crosswalk tools for J-codes including J7330.

Conclusion

HCPCS Code J7330 is one of the more documentation-intensive codes in orthopedic billing. Two-stage procedures, carrier judgment Medicare coverage, buy-and-bill reimbursement mechanics, and payer-specific prior authorization requirements all converge on a single claim. Getting any one element wrong – the companion CPT, the diagnosis code specificity, or the prior authorization reference – sends a high-cost biologic claim to denial.

Practices billing MACI procedures benefit from standardized workflows that connect the patient’s clinical record to the billing process at each stage. Pabau’s claims management platform helps regenerative medicine and orthopedic teams track authorization status, document each procedure stage, and submit clean claims the first time. To see how it fits your billing workflow, book a demo with the Pabau team.

Frequently Asked Questions